Back to Search
Start Over
High-throughput ex vivodrug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
- Source :
- Translational Oncology; January 2022, Vol. 15 Issue: 1
- Publication Year :
- 2022
-
Abstract
- •We established patient-derived cancer cell (PDC) lines from NRAS-positive MM tumors.•We carried out high-throughput drug testing with PDCs against 527 oncology drugs.•PDCs were sensitive to PI3K, mTOR, PLK1, MEK, ERK, and RAF inhibitors.•Drug combination synergies were identified.•Our results support application of PDCs for functional drug testing.
Details
- Language :
- English
- ISSN :
- 19447124 and 19365233
- Volume :
- 15
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Translational Oncology
- Publication Type :
- Periodical
- Accession number :
- ejs58312451
- Full Text :
- https://doi.org/10.1016/j.tranon.2021.101290